Mehmet Artaç

Mehmet Artaç

Necmettin Erbakan University - Konya / Türkiye
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 212295
Necmettin Erbakan Üniversitesi
person_outline Mehmet Artaç's MOST POPULAR ARTICLES
1-) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerNew England Journal of Medicine 377 (20), 1919-1929, 201739632017
2-) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCSJ Antonia, SJ (Antonia, [3] Villegas, A (Villegas, A.) [2], ...New England Journal of Medicine 379 (24), 2342-2350, 201825762018
3-) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer[2] Colombo, N (Colombo, N.) [1], C Dubot, C (Dubot, ...New England Journal of Medicine 385 (20), 1856-1867, 20215252021
4-) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerHMS Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J ...New England Journal of Medicine 390 (10), 875-888, 20242552024
5-) Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trialY Cheng, L Han, L Wu, J Chen, H Sun, G Wen, Y Ji, M Dvorkin, J Shi, ...Jama 328 (12), 1223-1232, 20222432022